Advertisement

Oncology / Hematology General

Hemostasis is Impair by GGCX Mutants That Lack Processivity and Full Carboxylation

Nov 09, 2022

Multiple carboxylated Glus (Glas) is produced by γ-Glutamyl carboxylase (GGCX) in vitamin K-dependent (VKD) proteins, which are necessary for their activities. For a study, researchers demonstrated t...

Relapse of MYC-amplified Medulloblastoma is Associated With OLIG2

Nov 09, 2022

The researchers compared radiation sensitivity in OLIG2-high and OLIG2-low tumors in patient-derived xenograft (PDX) lines and assessed OLIG2 expression in a panel of mouse MYC-amplified medulloblast...

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

Nov 09, 2022

Cancer screening, prevention, and therapy can be made more specific to each individual with the help of knowledge about inherited germline variations. Patients with locally advanced or metastatic urot...

Safety, Immunogenicity, and 1-Year Efficacy of UCPVax in Patients With Refractory Advanced NSCLC

Nov 07, 2022

The universal cancer peptide-based vaccination (UCPVax) induces a CD4+ T helper-1 response that is directed against telomerase by combining two carefully chosen helper peptides. In the phase Ib/IIa st...

AENEAS: Aumolertinib Vs. Gefitinib as First-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Exon 19 Deletion or L858R Mutations

Nov 07, 2022

A brand-new third-generation epidermal growth factor receptor tyrosine kinase inhibitor authorized in China is called aumolertinib (formerly known as almonertinib; HS-10296). Researchers compared the ...

Therapy for Stage IV NSCLC With Driver Alterations

Nov 07, 2022

For a study, researchers updated the 2021 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic treatment for patients with stage IV non-small-cell lung cancer (NSCLC) with driver change...

HSCT for Adolescents & Adults with Inborn Errors of Immunity

Nov 07, 2022

For newborns and children with multiple inborn errors of immunity (IEI), allogeneic hematopoietic stem cell transplantation (HSCT) is the gold standard curative treatment; nevertheless, adolescents an...

High-Dose Vitamin C Plus FOLFOX ± Bevacizumab Vs. FOLFOX ± Bevacizumab in Unresectable Untreated mCRC

Nov 07, 2022

This study's primary objective was to evaluate the efficacy and safety of high-dose vitamin C in combination with FOLFOX ± bevacizumab against FOLFOX ± bevacizumab as first-line treatment for patien...

Longitudinal Outcome of Unrelated Allogeneic Stem Cell Transplantation for Ref/Rel AML Over Two Decades

Nov 07, 2022

Results of unrelated transplantation for primary refractory/relapsed (ref/rel) acute myeloid leukemia (AML) were compared between 2 cohorts based on transplant year (2000-2009 and 2010-2019). The Cox ...

Impaired Chromatin Remodeling: GS plus Nivolumab in ABTC

Nov 04, 2022

Researchers' prior research indicated that the combination of modified gemcitabine and S-1 (GS) was an effective regimen for patients with advanced biliary tract cancer (ABTC). They present data from ...

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced NSCLC

Nov 03, 2022

In the CHOICE-01 research, toripalimab and chemotherapy were used as the first-line therapy for advanced non-small-cell lung cancer (NSCLC), and their effectiveness and safety were examined. Advanc...

Progression and Survival of Monoclonal B-cell lymphocytosis (MBL)

Nov 03, 2022

A typical hematological premalignant disease that is understudied in screening cohorts is monoclonal B-cell lymphocytosis (MBL). The size of the B-cell clone allows MBL to be divided into low-count (L...

Loss of Sphingosine Kinase 2 Promotes the HSCs Expansion

Nov 03, 2022

During myelosuppressive injury or age, hematopoietic stem cells (HSCs) have diminished abilities to adequately replace and maintain the hematopoietic system. The objective of enlarging and renewing HS...

Prognostic Impact of NPM1 & FLT3 Mutations in AML Patients

Nov 03, 2022

The oral azacitidine (Oral-AZA) was tested in patients with acute myeloid leukemia (AML) in the first remission following intensive chemotherapy (IC) who were not candidates for hematopoietic stem cel...

Nivolumab & Gemcitabine in Recurrent or Metastatic NPC Patients

Nov 02, 2022

In this trial, the effectiveness and safety of nivolumab with gemcitabine were assessed for patients with nasopharyngeal carcinoma (NPC) who had previously been treated with platinum-based chemotherap...

ARX788, Anti-HER2 ADC, for HER2-Positive MBC Treatment

Nov 02, 2022

ARX788 is a novel antibody-drug conjugate (ADC) that combines an anti-HER2 mAb with a potent tubulin inhibitor payload AS269 through site-specific conjugation to the antibody. AS269 is an unnatural am...

Omission of Upfront CSI in Low-Risk WNT-Pathway Medulloblastoma

Nov 02, 2022

There are 4 molecular subgroups of medulloblastoma: wingless (WNT), sonic hedgehog (SHH), group 3, and group 4. Treatment for medulloblastoma that follows the WNT route is being weakened because of it...

A Study of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, And Alveolar Rhabdomyosarcoma

Nov 02, 2022

Placental growth factor (PlGF) and its receptor neuropilin 1 are increased in malignant embryonal tumors and drive tumor progression by boosting cell proliferation, survival, and metastasis. In orthot...

Differentiated Thyroid Cancer: Cabozantinib Approval Summary

Nov 01, 2022

On September 17, 2021, the FDA approved cabozantinib (Cabometyx; Exelixis, Inc.) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differe...

Radioiodine Incorporation into RR-TC with MAPK Inhibition (ERRITI)

Nov 01, 2022

In radioiodine-resistant, resectable thyroid cancer, inhibition of mitogen-activated protein kinases (MAPK) restored iodine incorporation (redifferentiation) (RR-TC). However, in BRAFV600E-mutant (BRA...